Replies to post #2763 on Repros Therapeutics Inc (RPRX)

[agcmd]

A few comments -

1. This group was normally aging males, not those with hypogonadotrophic hypogonadism. The latter may have had a greater effect on testosterone levels with an intervention.
2. Oral tesosterone...
3. The significance of this intervention on the metabolic syndrome is limited, given advanced age and testosterone preparation used. I'd be interested to see how the measured insulin sensitivity.

[io_io]

dewophile - yes very interesting thread....


a) I also note that the trial had a size of 230 patients - this is a very small trial relative to the population under consideration, and the trends observed would likely be proven in appropriately-sized trials ..... think : partner.


http://investorshub.advfn.com/boards/read_msg.asp?message_id=25669126


b) This bit bothers me:

At the end of the study, nearly half of those taking testosterone exhibited the collection of symptoms known as metabolic syndrome -- a fat midsection and other conditions that can lead to heart disease and diabetes. However the difference in metabolic syndrome rates between testosterone takers and placebo takers was not considered statistically significant.

The way it is written makes it look as though T performed WORSE on this score - surely this is not what they meant to imply ?


c) Finally I notice your posts have become more orderly - anything changed in Ur life ? U sound more settled R something like that. Maybe my imagination.....